Abbott‘s (NYSE:ABT) sensor-enabled Advisor HD Grid mapping catheter has won CE Mark approval in the European Union.
The device is designed for use in any chamber of the heart during cardiac ablation. Physicians use mapping catheters to identify areas of cardiac tissue that are responsible for sending erratic electrical signals that cause arrhythmias.
Abbott touted its device as having a first-of-its-kind grid configuration of electrodes that improves data collection.
Linear or circular mapping catheters sometimes experience signal disruptions when the orientation of the catheter changes, Abbott explained. But its Advisor HD Grid device is designed to avoid signal loss by collecting data horizontally and vertically along a grid that’s configured with 16 sensors.
The catheter captures data through both impedance and magnetic collection. Using that data, the Advisor HD Grid catheter creates detailed and anatomically-accurate 3D models of the heart.
Abbott’s device, combined with the EnSite Precision cardiac mapping system, allows doctors to create a map detailing the differences between healthy tissue and the tissue causing a patient’s arrhythmias.
